Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Behavioral effects of multiple-dose oxytocin treatment in autism: a randomized, placebo-controlled trial with long-term follow-up
Sylvie Bernaerts, Bart Boets, Guy Bosmans, et al.
Molecular Autism (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 83

Showing 1-25 of 83 citing articles:

An Update on Psychopharmacological Treatment of Autism Spectrum Disorder
Ramkumar Aishworiya, Tatiana Valica, Randi J. Hagerman, et al.
Neurotherapeutics (2022) Vol. 19, Iss. 1, pp. 248-262
Open Access | Times Cited: 146
Signalling pathways in autism spectrum disorder: mechanisms and therapeutic implications
Chen-Chen Jiang, Lishan Lin, Sen Long, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 126
Chronic oxytocin administration stimulates the oxytocinergic system in children with autism
Matthijs Moerkerke, Nicky Daniëls, Laura Tibermont, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 16
Developmental programming of oxytocin through variation in early-life stress: Four meta-analyses and a theoretical reinterpretation
Bruce J. Ellis, Alexander J. Horn, C. Sue Carter, et al.
Clinical Psychology Review (2021) Vol. 86, pp. 101985-101985
Open Access | Times Cited: 63
Repetitive Restricted Behaviors in Autism Spectrum Disorder: From Mechanism to Development of Therapeutics
Junbin Tian, Xuping Gao, Li Yang
Frontiers in Neuroscience (2022) Vol. 16
Open Access | Times Cited: 59
Oxytocin and vasopressin: Signalling, behavioural modulation and potential therapeutic effects
Mariana Rae, Mariana Lemos Duarte, Ivone Gomes, et al.
British Journal of Pharmacology (2021) Vol. 179, Iss. 8, pp. 1544-1564
Open Access | Times Cited: 56
Infrequent Intranasal Oxytocin Followed by Positive Social Interaction Improves Symptoms in Autistic Children: A Pilot Randomized Clinical Trial
Jiao Le, Lan Zhang, Weihua Zhao, et al.
Psychotherapy and Psychosomatics (2022) Vol. 91, Iss. 5, pp. 335-347
Open Access | Times Cited: 55
Effects of multiple-dose intranasal oxytocin administration on social responsiveness in children with autism: a randomized, placebo-controlled trial
Nicky Daniëls, Matthijs Moerkerke, Jean Steyaert, et al.
Molecular Autism (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 29
The effects of oxytocin administration on social and routinized behaviors in autism: A preregistered systematic review and meta-analysis
Kristin Audunsdottir, Alina M. Sartorius, Heemin Kang, et al.
Psychoneuroendocrinology (2024) Vol. 167, pp. 107067-107067
Open Access | Times Cited: 11
Toward effective oxytocin interventions in autism: Overcoming challenges and harnessing opportunities
Grazia Ricchiuti, Elise Tuerlinckx, A. Taillieu, et al.
Journal of Psychopharmacology (2025)
Closed Access | Times Cited: 1
A white paper on a neurodevelopmental framework for drug discovery in autism and other neurodevelopmental disorders
CM Díaz-Caneja, Matthew W. State, RJ Hagerman, et al.
European Neuropsychopharmacology (2021) Vol. 48, pp. 49-88
Open Access | Times Cited: 42
Endogenous Oxytocin Levels in Autism—A Meta-Analysis
Matthijs Moerkerke, Mathieu Peeters, Lyssa de Vries, et al.
Brain Sciences (2021) Vol. 11, Iss. 11, pp. 1545-1545
Open Access | Times Cited: 42
Effect of a novel nasal oxytocin spray with enhanced bioavailability on autism: a randomized trial
Hidenori Yamasue, Masaki Kojima, Hitoshi Kuwabara, et al.
Brain (2021) Vol. 145, Iss. 2, pp. 490-499
Open Access | Times Cited: 42
Cannabidiol for the treatment of autism spectrum disorder: hope or hype?
João Francisco Cordeiro Pedrazzi, Frederico Rogério Ferreira, Danyelle Silva-Amaral, et al.
Psychopharmacology (2022) Vol. 239, Iss. 9, pp. 2713-2734
Closed Access | Times Cited: 31
Pharmacological intervention for irritability, aggression, and self-injury in autism spectrum disorder (ASD)
Michelle Iffland, Nuala Livingstone, Mikaela Jorgensen, et al.
Cochrane library (2023) Vol. 2023, Iss. 10
Closed Access | Times Cited: 16
Heterogeneity in response to repeated intranasal oxytocin in schizophrenia and autism spectrum disorders: A meta‐analysis of variance
Daniel Martins, Maria Paduraru, Yannis Paloyelis
British Journal of Pharmacology (2021) Vol. 179, Iss. 8, pp. 1525-1543
Open Access | Times Cited: 36
Oxytocin-based therapies for treatment of Prader-Willi and Schaaf-Yang syndromes: evidence, disappointments, and future research strategies
Ferdinand Althammer, Françoise Muscatelli, Valery Grinevich, et al.
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 26
Available Treatments for Autism Spectrum Disorder: From Old Strategies to New Options
Liliana Dell’Osso, Chiara Bonelli, Federico Giovannoni, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 3, pp. 324-324
Open Access
Oxytocin and autism: Insights from clinical trials and animal models
Chuan Xing, Xiang Yu
Current Opinion in Neurobiology (2025) Vol. 92, pp. 103015-103015
Closed Access
Exploring genetic and environmental contributions to autism spectrum disorder: insights from rodent models
Marta Marlena Ziętek, Maria Pia Viscomi, Joanna Czyrska, et al.
Animal Science Papers and Reports (2025) Vol. 43, Iss. 1, pp. 33-48
Closed Access
Correction of vasopressin deficit in the lateral septum ameliorates social deficits of mouse autism model
Amélie M. Borie, Yann Dromard, Gilles Guillon, et al.
Journal of Clinical Investigation (2020) Vol. 131, Iss. 2
Open Access | Times Cited: 36
Intranasal Peptide Therapeutics: A Promising Avenue for Overcoming the Challenges of Traditional CNS Drug Development
Meenakshi Bose, Gabriela Farias Quipildor, Michelle E. Ehrlich, et al.
Cells (2022) Vol. 11, Iss. 22, pp. 3629-3629
Open Access | Times Cited: 20
Multiple Aspects of Inappropriate Action of Renin–Angiotensin, Vasopressin, and Oxytocin Systems in Neuropsychiatric and Neurodegenerative Diseases
Ewa Szczepańska‐Sadowska, Agnieszka Wsół, Agnieszka Cudnoch-Jędrzejewska, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 4, pp. 908-908
Open Access | Times Cited: 19
Therapeutic potential of CBD in Autism Spectrum Disorder
João Francisco Cordeiro Pedrazzi, Lucas Hassib, Frederico Rogério Ferreira, et al.
International review of neurobiology (2024), pp. 149-203
Closed Access | Times Cited: 4
Optimal dose of oxytocin to improve social impairments and repetitive behaviors in autism spectrum disorders: meta-analysis and dose–response meta-analysis of randomized controlled trials
Yingying Zhang, Xiaolu Zhang, Linghong Huang
Frontiers in Psychiatry (2025) Vol. 15
Open Access
Page 1 - Next Page

Scroll to top